1. Bringing Open Science to The Montreal Neurological Institute
Guy Rouleau MD PhD FRCP(C) OQ
Director, Montreal Neurological Institute and Hospital and
Department of Neurology and Neurosurgery McGill University

2. The pace of discovery of new treatments is slow
Diseases of the brain and nervous system are one of the most compelling unmet medical needs of our time
The pace of discovery of new treatments is slow

3. The Montreal Neurological Institute (MNI)
Founded in 1934 by renowned neurosurgeon Dr. Wilder Penfield
An integrated neuroscience research and clinical center
A place where we can make real advances in neuroscience and our understanding and treatment of neurological diseases

4. The result: accelerated discovery, new treatments,
Open Science as a mission enabler
From its inception, The Neuro’s singular mission has been to deploy scientific research in service of patients, families and society
We see Open Science a means to expand the impact of our research by sharing it with a global community of like-minded scientists
The result: accelerated discovery, new treatments,

5. Open Commercialization
Pushing innovation forward
Open Access
Open Data
Open Access
Open Data
Open Access
Open Data
Open IP
Open Biobank
Open Commercialization

6. An informed decision Defined Open Science for the MNI
Mapped existing open science activities at the MNI
Consultation process (over a year) with MNI Faculty, staff and students (seminars, polls, town halls, and Q and A sessions)
Social science study (structured questionnaires) of potential barriers and limitation related to Open Science by an independent research group
Established Guiding Principles with final buy-in of all MNI members

7. Five guiding principles
Principle 1: Public release of scientific data and resources
No later than publication
Principle 2: External research partnerships
Same as Principle 1
Principle 3: The MNI Biobank (NEURO-C-BIGR)
Free sharing of samples and other resources within the limits of supply and respecting patient confidentiality
Principle 4: Intellectual Property
Will not be filed
Principle 5: Autonomy
Will be respected

8. Three core initiatives
The MNI Biobank (NEURO-C-BIGR)
Brain imaging, clinical, demographic, genetic (DNA), and cellular data and samples from patients with neurological disorders, with data opened up to the world
The Open Drug Discovery Platform
Unique public-private partnership with collaboration of the Structural Genomic Consortium and CDRD. Three diseases will be targeted initially: brain tumours (GBM), ALS, and Parkinson’s
The Open Science Impact Assessment Committee
Findings of the Committee will be made available to other institutions wishing to adopt an Open Science Policy

9. Implementation timeline…
Renovations
Continued operations
Data Management and Dissemination
Project Management
Biobank expansion
Biobank launch
Cell-based Platforms upgrades and renovations
Cell-based Platforms launch
Open Drug Discovery
SGC Partnership
Clinical Trials begin
2016

10. Genetics of ALS Guy A. Rouleau, MD, PhD, FRCP(C)
Montreal Neurological Institute and Hospital
University of McGill
This paper I’m about to present concerns a very contemporary and significant technique. It’s just been recently discovered, and is still in the process of development. Imagine being able repress any gene or combination of genes you want in a cell. That’s what RNA interference proposes. For those of you with honours projects, think of a gene of which it might be interesting to see the effects if it were suppressed. This is something which you can use to impress your honours professor. Suggest using RNAi for the gene of interest.

11. Questions?

13. Five guiding principles
Principle 1: Public release of scientific data and resources
The MNI and its researchers will render all positive and negative numerical data, models used, data sources, reagents, algorithms, software and other scientific resources publicly available no later than the publication date of the first article that relies on this data or resource.
Principle 2: External research partnerships
All data and scientific resources generated through research partnerships – whether with commercial, philanthropic, or public sector actors – are to be released on the same basis as set out in Principle 1.

14. Five guiding principles
Principle 3: The MNI Biobank (NEURO-C-BIGR)
The MNI Biobank supports knowledge creation and innovation by maximizing the long-term value of the contributions made by research participants and the scientific resources created by MNI researchers and their collaborators. The Biobank will generate revenues, while continuing to enrich and strengthen its informational content and the knowledge it provides. In the conduct of MNI Biobank, the MNI recognizes the primacy of safeguarding the dignity and privacy of patient-participants, and respecting the rights and duties owed them through the informed consent process.

15. Five guiding principles
Principle 4: Intellectual Property
Subject to patient confidentiality and informed consent given, neither the MNI nor its researchers in their capacity as employees or consultants of McGill – MNI unit will obtain patent protection or assert data protection rights in respect of any of their research.
Principle 5: Autonomy
The MNI supports the autonomy of its stakeholders, including but not limited to researchers, staff, trainees and patients, through recognizing their right to decline to participate in research and associated activities under an OS framework. However, the MNI will not support activities that compromise the previously outlined OS principles.